Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.96 |
| ▸ | HPGD | P15428 | 7/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.96 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | HMGB1 | P09429 | 2/20 | 0.59 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | CA6 | P23280 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 5/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13826872 | 1.00 | HSD17B10 (0.96) | HSD17B10KDM4EHPGDALDH1A1LMNA | |
| SCHEMBL30111333 | 1.00 | HSD17B10 (0.96) | HSD17B10KDM4EHPGDALDH1A1LMNA | |
| Salsalate SCHEMBL15562 | 0.98 | HSD17B10 (1.00) | HSD17B10KDM4EHPGDALDH1A1LMNA | |
| Salsalate SCHEMBL2025628 | 0.98 | HSD17B10 (1.00) | HSD17B10KDM4EHPGDALDH1A1LMNA | |
| Salsalate SCHEMBL29362887 | 0.98 | HSD17B10 (1.00) | HSD17B10KDM4EHPGDALDH1A1LMNA | |
| Salsalate SCHEMBL25177171 | 0.96 | KDM4E (0.96) | HSD17B10KDM4EHPGDALDH1A1LMNA | |
| Salsalate SCHEMBL1802439 | 0.96 | HSD17B10 (0.96) | HSD17B10KDM4EHPGDALDH1A1LMNA | |
| Salsalate SCHEMBL9624915 | 0.96 | HSD17B10 (0.96) | HSD17B10KDM4EHPGDALDH1A1LMNA | |
| Salsalate SCHEMBL25260636 | 0.96 | HSD17B10 (0.96) | HSD17B10KDM4EHPGDALDH1A1LMNA | |
| Salsalate SCHEMBL12477400 | 0.96 | HSD17B10 (0.96) | HSD17B10KDM4EHPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220480-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF NLRP3 INFLAMMASOME MEDIATED IL-1BETA DEPENDENT DISORDERS | INST NAT SANTE RECH MED (FR) | 2022-07-14 | — | — | US | disclosed |
| WO-2022084300-A1 | METHODS FOR DIAGNOSIS AND MONITORING FORM OF CORONAVIRUS INFECTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-04-28 | — | — | WO | disclosed |
| EP-3956446-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF NLRP3 INFLAMMASOME MEDIATED IL-1BETA DEPENDENT DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-02-23 | — | — | EP | disclosed |
| WO-2022008597-A1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFECTIOUS DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-01-13 | — | — | WO | disclosed |
| WO-2021198511-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF SARS-COV-2 INFECTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-10-07 | — | — | WO | disclosed |
| WO-2020212484-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF NLRP3 INFLAMMASOME MEDIATED IL-1BETA DEPENDENT DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-10-22 | — | — | WO | disclosed |
| US-20170368079-A1 | ANTI-INFLAMMATORY AND ANTIDIABETIC AGENTS | MYLARI BANAVARA L (US) | 2017-12-28 | — | — | US | disclosed |
| US-20140323444-A1 | ANTI-INFLAMMATORY AND ANTIDIABETIC AGENTS | MYLARI BANAVARA L (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323444-A1 | ANTI-INFLAMMATORY AND ANTIDIABETIC AGENTS | MYLARI BANAVARA L (US) | 2014-10-30 | — | — | US | disclosed |
| US-20130252926-A1 | METFORMIN SALTS OF SALICYLIC ACID AND IT CONGENERS | MYLARI BANAVARA L (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252926-A1 | METFORMIN SALTS OF SALICYLIC ACID AND IT CONGENERS | MYLARI BANAVARA L (US) | 2013-09-26 | — | — | US | disclosed |
| US-8440723-B2 | Metformin salts of salicylic acid and its congeners | MYLARI BANAVARA L (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440723-B2 | Metformin salts of salicylic acid and its congeners | MYLARI BANAVARA L (US) | 2013-05-14 | — | — | US | disclosed |
| WO-2012154392-A1 | METFORMIN SALTS OF SALICYLIC ACID AND ITS CONGENERS | MYLARI BANAVARA L (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120289485-A1 | Metformin Salts of Salicylic Acid and Its Congeners | MYLARI BANAVARA L (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289485-A1 | Metformin Salts of Salicylic Acid and Its Congeners | MYLARI BANAVARA L (US) | 2012-11-15 | — | — | US | disclosed |
| US-8013184-B2 | Manufacture process of organic compounds | NOVARTIS AG (CH) | 2011-09-06 | — | — | US | disclosed |
| WO-2010006046-A1 | NSAID DELIVERY FROM POLYARYLATES | TYRX PHARMA, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| US-20090234010-A1 | MANUFACTURE PROCESS OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368079-A1 | ANTI-INFLAMMATORY AND ANTIDIABETIC AGENTS | IL6, TNF, FABP4 | HSD17B10 823/4885KDM4E 2572/4885HPGD 400/4885 |
| US-20220220480-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF NLRP3 INFLAMMASOME MEDIATED IL-1BETA DEPENDENT DISORDERS | LITAF, APAF1, CASP1 | HSD17B10 4756/4885KDM4E 4180/4885HPGD 3589/4885 |
| US-20120289485-A1 | Metformin Salts of Salicylic Acid and Its Congeners | TLR6, SUCNR1, SLC5A1 | HSD17B10 1094/4885KDM4E 1375/4885HPGD 1445/4885 |
| US-20130252926-A1 | METFORMIN SALTS OF SALICYLIC ACID AND IT CONGENERS | SUCNR1, TLR6, SLC5A1 | HSD17B10 956/4885KDM4E 1444/4885HPGD 1412/4885 |
| US-20140323444-A1 | ANTI-INFLAMMATORY AND ANTIDIABETIC AGENTS | IL6, TNF, FABP4 | HSD17B10 744/4885KDM4E 2697/4885HPGD 335/4885 |
| US-20090234010-A1 | MANUFACTURE PROCESS OF ORGANIC COMPOUNDS | NT5C, DDC, AADAC | HSD17B10 2724/4885KDM4E 1146/4885HPGD 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.